Page 102 - Read Online
P. 102
Page 10 of 10 Sell et al. Mini-invasive Surg 2024;8:3 https://dx.doi.org/10.20517/2574-1225.2023.105
67. Au WY, Kim SJ, Yiu HHY, et al. Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years
after initial remission. Am J Hematol 2010;85:362-3. DOI PubMed
68. Kim SJ, Park Y, Kim BS, Kim I, Ko YH, Kim WS. Extranodal natural killer/T-cell lymphoma with long-term survival and repeated
relapses: does it indicate the presence of indolent subtype? Korean J Hematol 2012;47:202-6. DOI PubMed PMC
69. Kommalapati A, Tella SH, Ganti AK, Armitage JO. Natural killer/T-cell neoplasms: analysis of incidence, patient characteristics, and
survival outcomes in the United States. Clin Lymphoma Myeloma Leuk 2018;18:475-9. DOI PubMed
70. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001;2:683-90. DOI
PubMed
71. Girod D, Hanna E, Marentette L. Esthesioneuroblastoma. Head Neck 2001;23:500-5. DOI PubMed
